AKT1 exons 4 and 7
PIK3CA exons 2, 5, 7, 8, 10, 14, 19 and 21
BRAF exons 11 and 15
NRAS exons 2-4
KRAS exons 2-4
CRC Mutation Panel by NGS
Oncomine genomic profiling
Looking to order a test?
We’ve provided helpful links to make ordering easy.Find a Requisition
All specimens should be accompanied by a requisition.Submitting Specimens
Learn about how to properly label and where to ship specimens.Order Kits and Supplies
MLabs provides all the supplies necessary for the collection of specimens.Test FAQ
Visit our provider FAQ and learn about common questions to ordering tests.
Molecular testing of colorectal cancer (CRC) is currently the standard of care for guiding the use FDA-approved targeted therapies such as anti-EGFR and anti-PDL1 antibodies. In addition, more investigational clinical actions are often employed for patients with advanced stage CRC including the use FDA-approved drugs for an off-label indication and enrollment in clinical trials. This assay is designed to provide comprehensive molecular results relevant for both standard of care and emerging/investigational clinical actions. This DNA and RNA based, next-generation sequencing test targets 50 genes to detect substitution and insertion/deletion mutations (35 genes), gene amplifications (19 genes), and gene fusions (21 genes). Detectable variants relevant for CRC include, but are not limited to, mutations of KRAS, NRAS, BRAF, PIK3CA, and AKT1; amplification of ERBB2, FGFR1, KRAS, and MYC; and rearrangements of ALK. Importantly, microsatellite instability testing is NOT included in this assay and must be ordered separately if clinically indicated. A complete list of sequenced regions, genes assessed for amplification and detectable fusion transcripts is available below.
Interpretive Report Provided
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
For formalin-fixed, paraffin-embedded tissue, a block containing an area with a high percentage of neoplastic cells (for micro-/macro-dissection) is preferred. Unstained, UNBAKED slides (5-8, 10-micron slides; 10-15 if few neoplastic cells are present) with associated H&E stained slide are also acceptable. Decalcified tissue or other fixatives will be accepted and the assay attempted, however these may result in failed testing due to degraded nucleic acid. Both blocks and slides should be stored at room temperature. A Diff-Quik or Papanicolaou stained aspirate smear (preferable containing a high percentage and overall amount of neoplastic cells) is also acceptable. Store at room temperature.